These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 378673)
1. Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide. Sonnhag C; Karlsson E Eur J Clin Pharmacol; 1979 Jun; 15(5):311-7. PubMed ID: 378673 [TBL] [Abstract][Full Text] [Related]
2. Antiarrhythmic efficacy of N-acetylprocainamide in patients with premature ventricular contractions. Lee WK; Strong JM; Kehoe RF; Dutcher JS; Atkinson AJ Clin Pharmacol Ther; 1976 May; 19(5 Pt 1):508-14. PubMed ID: 776488 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic interaction of N-acetyl procainamide and procainamide in humans. Funck-Brentano C; Light RT; Lineberry MD; Wright GM; Roden DM; Woosley RL J Cardiovasc Pharmacol; 1989 Sep; 14(3):364-73. PubMed ID: 2476614 [TBL] [Abstract][Full Text] [Related]
4. [A new anti-arrhythmia drug. II. Comparative studies of the effects of a new acyl derivative of procainamide, procainamide and N-acetylprocainamide on blood pressure and the electrocardiogram in rabbits]. Kusowska J Acta Pol Pharm; 1989; 46(1):90-7. PubMed ID: 2479226 [TBL] [Abstract][Full Text] [Related]
5. Electrophysiologic properties and antiarrhythmic mechanisms of intravenous N-acetylprocainamide in patients with ventricular dysrhythmias. Sung RJ; Juma Z; Saksena S Am Heart J; 1983 May; 105(5):811-9. PubMed ID: 6189384 [TBL] [Abstract][Full Text] [Related]
6. Procainamide: clinical pharmacology and efficacy against ventricular arrhythmias. Giardina EG Ann N Y Acad Sci; 1984; 432():177-88. PubMed ID: 6084435 [TBL] [Abstract][Full Text] [Related]
7. Comparative evaluation of intravenous phenytoin, procainamide and practolol in the acute treatment of ventricular arrhythmias. Karlsson E; Kinman A; Sonnhag C Eur J Clin Pharmacol; 1977; 11(1):1-6. PubMed ID: 832652 [TBL] [Abstract][Full Text] [Related]
8. Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Roden DM; Reele SB; Higgins SB; Wilkinson GR; Smith RF; Oates JA; Woosley RL Am J Cardiol; 1980 Sep; 46(3):463-8. PubMed ID: 6158263 [TBL] [Abstract][Full Text] [Related]
9. Dose-ranging trial of N-acetylprocainamide in patients with premature ventricular contractions. Atkinson AJ; Lee WK; Quinn ML; Kushner W; Nevin MJ; Strong JM Clin Pharmacol Ther; 1977 May; 21(5):575-87. PubMed ID: 322922 [TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic potency of N-acetylprocainamide. Elson J; Strong JM; Lee WK; Atkinson AJ Clin Pharmacol Ther; 1975 Feb; 17(2):134-40. PubMed ID: 1122675 [TBL] [Abstract][Full Text] [Related]
11. [New anti-arrhythmia drug. III. Comparative studies of the effects of N-propionylprocainamide, procainamide and N-acetylprocainamide on hemodynamics and cardiac blood flow]. Kusowska J; Polakowski P Acta Pol Pharm; 1989; 46(2):187-94. PubMed ID: 2483600 [TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacology and antiarrhythmic efficacy of N-acetylprocainamide. Winkle RA; Jaillon P; Kates RE; Peters F Am J Cardiol; 1981 Jan; 47(1):123-30. PubMed ID: 6161534 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of N-acetylprocainamide in long-term treatment of ventricular arrhythmias. Atkinson AJ; Lertora JJ; Kushner W; Chao GC; Nevin MJ Clin Pharmacol Ther; 1983 May; 33(5):565-76. PubMed ID: 6188570 [TBL] [Abstract][Full Text] [Related]
15. Electrophysiologic evaluation of the antiarrhythmic effects of N-acetylprocainamide for ventricular tachycardia secondary to coronary artery disease. Wynn J; Miura DS; Torres V; Flowers D; Keefe D; Williams S; Somberg JC Am J Cardiol; 1985 Nov; 56(13):877-81. PubMed ID: 2414983 [TBL] [Abstract][Full Text] [Related]
16. Comparison of the pharmacokinetic and pharmacodynamic properties of procainamide and N-acetylprocainamide. Atkinson AJ; Ruo TI; Piergies AA Angiology; 1988 Jul; 39(7 Pt 2):655-67. PubMed ID: 2457345 [TBL] [Abstract][Full Text] [Related]
17. Torsade de pointes induced by N-acetylprocainamide. Chow MJ; Piergies AA; Bowsher DJ; Murphy JJ; Kushner W; Ruo TI; Asada A; Talano JV; Atkinson AJ J Am Coll Cardiol; 1984 Sep; 4(3):621-4. PubMed ID: 6206104 [TBL] [Abstract][Full Text] [Related]
18. Correlation of the electrophysiological and antiarrhythmic properties of the N-acetyl metabolite of procainamide with plasma and tissue drug concentrations in the dog. Bagwell EE; Walle T; Drayer DE; Reidenbert MM; Pruett JK J Pharmacol Exp Ther; 1976 Apr; 197(1):38-48. PubMed ID: 1263131 [TBL] [Abstract][Full Text] [Related]
19. Cumulation of N-acetylprocainamide, an active metabolite of procainamide, in patients with impaired renal function. Drayer DE; Lowenthal DT; Woosley RL; Nies AS; Schwartz A; Reidenberg MM Clin Pharmacol Ther; 1977 Jul; 22(1):63-9. PubMed ID: 872496 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous quantification of procainamide and N-acetylprocainamide with high-performance liquid chromatography. Carr K; Woosley RL; Oates JA J Chromatogr; 1976 Dec; 129():363-8. PubMed ID: 1002795 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]